Nov. 19, 2015—Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has received a 2015 Cancer Clinical Investigator Team Leadership Award (CCITLA) from the National Cancer Institute (NCI).
Jul. 30, 2015—In a town full of amazing singers, Nashville songstress Dawn Sears’ voice was something special.
Jun. 11, 2015—Pierre Massion, M.D., director of the Thoracic Program and an Ingram Professor of Cancer Research at Vanderbilt-Ingram Cancer Center, has been recognized for his pioneering work in lung cancer by the LUNGevity Foundation.
Apr. 2, 2015—Vanderbilt-Ingram Cancer Center investigators have identified the mechanisms used by a gene and its binding protein to drive tumor growth in several forms of cancer, including non-small cell lung cancer.
Nov. 13, 2014—"Dawn Sears and Friends," a fundraiser to benefit lung cancer research at the Vanderbilt-Ingram Cancer Center, is scheduled for Nov. 30 at Depot Square in Gallatin, Tennessee. Reba McEntire, The Time Jumpers, Riders in the Sky and Olympic figure skating great Scott Hamilton will be featured.
Sep. 26, 2014—Tobacco smoking has been linked to approximately 2 million deaths among adult men and women in Asia in recent years, according to a new study that predicts a rising death toll.
Sep. 24, 2014—A new analysis of published studies found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common.
Sep. 18, 2014—Joe B. (Bill) Putnam Jr., M.D., Ingram Professor of Cancer Research and chair of the Department of Thoracic Surgery, and colleague Felix Fernandez, M.D., assistant professor of Surgery, Emory University School of Medicine, Atlanta, have received a grant to investigate the most effective forms of surgery to treat lung cancer patients.
Sep. 4, 2014—A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.